Vancouver, British Columbia--(Newsfile Corp. - February 12, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has retained Jolt Communications LLC ("Jolt") to lead its investor relations efforts.
Philip Young, CEO of Lobe, states, "We are pleased to work with Jolt in an effort to bolster our communications with the investment community. We have a compelling story at Lobe and look forward to sharing it with the investment community at large."
Jolt is a leader in investor relations, financial media, and research for microcap and small-cap stocks. Headquartered in New York City, Jolt has worked with dozens of companies assisting their communication efforts.
The program is designed to increase market awareness and provide improved visibility of the Company. The Company entered into a three (3) month engagement with Jolt, with an effective date of February 1, 2021 for US $250,000. Jolt does not have any interest, directly or indirectly in the Company or its securities, or any right to acquire such an interest.
About Lobe Sciences Ltd.
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information please contact:
Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Disclaimer for Forward Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, the effect of the marketing program on increasing market awareness and improved visibility, the pursuit of M&A initiatives, research and development using psychedelic compounds, the development of innovative devices and delivery mechanisms to improve mental health and wellness and growth of the business, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company's corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74332
